anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Aplisol (tuberculin PPD, diluted) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The solution is stabilized with polysorbate (Tween) 80, buffered with potassium and sodium phosphates and contains approximately 0.25% phenol as a preservative.

This product is ready for immediate use without further dilution.

The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis by the method of F.B. Seibert.1,2 Tuberculin PPD, diluted, is prepared from Tuberculin PPD which is clinically bioequivalent in potency to the standard PPD-S* (5 TU** per 0.1mL) of the U.S. Public Health Service, National Centers for Disease Control.

The potency of each lot of tuberculin PPD, diluted is determined in sensitized guinea pigs.
PURPOSE:To obtain a composition for oral cavity application effective in improving the residence in oral cavity, especially adsorption to the surface of tooth and preventing the formation of bacterial plaque by compounding cetyl pyridinium chloride and phytic acid or its derivative. CONSTITUTION:The objective composition can be produced by compounding >=0.0002wt.% and usually <=1wt.% of cetyl pyridinium chloride and >=1/10 pts.wt., usually 1/10 to 20 pts.wt. (based on 1 pt.wt. of the cetyl pyridinium chloride) of phytic acid or its derivative, mixing with desired components by conventional method and forming in the form of a drug. It can be used as tooth powder, tooth paste, gargle or troche or sprayed into oral cavity as aerosol. It can also be used as a tooth-application agent by impregnating in a dental floss or a toothpick.
Further improvements in therapy can only be achieved with a better understanding of the genomic landscape of ALK rearranged non-small cell lung cancer (NSCLC), specifically at the time of disease progression following treatment with ALK inhibitors. Recently, secondary ALK mutations, L1196M and G1269A have been described in patients with acquired resistance to crizotinib. A small subset of ALK positive lung cancer patients who progressed after treatment with ceritinib had tumors available for molecular analysis. Secondary mutations found included G1202R, F1174C, and F1174V. While this is interesting, an unbiased genomic study (exome or whole genome sequencing) using massively parallel sequencing at the time of disease progression is critical to fully understand the clonal evolution and the molecular mechanisms underpinning treatment resistance. To the best of the investigators' knowledge, such a study has not yet been reported.

The investigators believe the time is ripe now to comprehensively characterize genomic alterations using massively parallel sequencing technology of ALK driven adenocarcinoma of the lung to fully understand the clonal heterogeneity before therapy and fully understand the clonal evolution and the molecular mechanisms underpinning treatment resistance. A better understanding of genomic alterations through an unbiased comprehensive approach likely would lead to rationally designed therapy to augment response to ALK inhibitors.
DAYTRANA use may result in a persistent loss of skin pigmentation at and around the application site. Loss of pigmentation, in some cases, has been reported at other sites distant from the application site. Chemical leukoderma can mimic the appearance of vitiligo, particularly when the loss of skin pigmentation involves areas distant from the application site. Individuals with a history of vitiligo and/or a family history of vitiligo may be more at risk. Skin depigmentation may persist even after DAYTRANA use is discontinued. Monitor for signs of skin depigmentation, and advise patients to immediately inform their healthcare provider if changes in skin pigmentation occur. Discontinue use of the DAYTRANA in patients with chemical leukoderma.
PROBLEM TO BE SOLVED: To provide a new apoptosis-inducing agent derived from evening primrose and having high safety and provide a food, drink or drug containing the agent. SOLUTION: The apoptosis-inducing agent contains the extract of the whole grass, especially the seed of evening primrose as an active component. The seed of evening primrose is preferably defatted seed of evening primrose. The extraction solvent is preferably an ethanol/water mixture having an ethanol concentration of 70-85% (v/v). The apoptosis-inducing agent contains gallic acid, ellagic acid or pentagalloyl glucose as an active component. The present invention further relates to a food or drink containing the apoptosis-inducing agent and a drug containing the apoptosis-inducing agent.
Body mass index (BMI) is used to screen for under- or overweight. However, it is unknown whether BMI-screening in school children reduces the incidence of overweight and obesity. We aimed to summarise the knowledge on positive and negative consequences on BMI and weight-related perceptions and behaviours of BMI-screening followed by an intervention to prevent and/or address obesity. We performed a systematic literature search, April 2023, using the PubMed, ScienceDirect and Google Scholar databases. We included randomised controlled trials and observational studies, including children aged 6 to 18 years and examining BMI-screening in a school setting. The primary outcome measures were BMI and weight status. Secondary outcome measures were weight-related perceptions and behaviours. Three studies met the inclusion criteria; two randomised controlled trials and one observational study. All studies used BMI-screening followed by sending report cards to the parents. None of the studies found a change in BMI z-scores in school children. Screening could cause transitory body-dissatisfaction and increase peer weight talk, yet potentially reduce problematic weight behaviours like skipping meals or excessive dieting. Reporting BMI to parents may influence their perception of their children's weight status, but does not change behaviour. The sparse evidence available suggested that BMI screening followed by sending report cards to parents does not change BMI z-scores among children in primary, middle and high school. Studies using appropriate evidence-based weight management interventions as a follow-up are lacking. Such studies may improve future prevention, detection and treatment of weight-related issues.
The invention belongs to the field of biological engineeringThe technical field of the process, relates to a polypeptide with an anti-wrinkle function, a compound thereof and application thereof. The invention provides a polypeptide with an anti-wrinkle function, wherein the amino acid sequence of the polypeptide is shown as SEQ ID No. 1; the SEQ ID No.1 is: CEFMRNEFEEMQRR is added. The invention provides a compound containing the polypeptide, which comprises the polypeptide with the anti-wrinkle function and HAuCl 4 Ascorbic acid. The invention also provides application of the compound in preparation of cosmetics, wherein the cosmetics comprise any one of eye cream, face cream, essence and facial masks. The polypeptide with the anti-wrinkle function and the compound thereof provided by the invention have good stability, affinity and permeability, show good biocompatibility, and are used for relaxing paralysis of facial expression muscles, so that the effects of improving facial contours and eliminating or reducing wrinkles are achieved.
FIELD: biology, molecular biology, medicine. SUBSTANCE: invention relates to field of regulation of cell growth. Synthetic mutant genes Rb and p53 are mutated by alternation of nucleotides encoding amino acids in conservative homologous regions for nucleotides encoding nonconservative amino acids. Amino acid sequences are given in description. Mutated regions comprise the same amount, more or less amino acids as compared with the region of wild type. Synthetic mutant gene Rb is mutated by alternation of nucleotide sequence that encodes amino acids in phosphorylation sites of protein Rb. Plasmid is constructed on the basis of plasmid Rb HuBa cpr-1-neo-PQ with incorporation of mutant gene Rb or p53 in it. Cellular proliferation is inhibited by insertion of these plasmids into nonmalignant proliferating cell. Retinoblastoma protein is encoded by synthetic mutant gene Rb. Retinoblastoma protein p53 is encoded by synthetic mutant gene p53. Retinoblastoma protein p53 is inserted into cell for induction of apoptosis. Proliferation of tumor cell with mutation of cyclin protein is inhibited by insertion of retinoblastoma protein p53 into cell. Invention ensures to treat pathological cellular-proliferative states. EFFECT: valuable medicinal properties. 17 cl, 14 dwg, 2 tbl
The invention relates to polysaccharide with antitumor and immunologic adjuvant function, a preparation method thereof, a medicine composite using the same as an active component, and an application oThe invention relates to polysaccharide with antitumor and immunologic adjuvant function, a preparation method thereof, a medicine composite using the same as an active component, and an application of the same in tumor treatment and adjuvant used as vaccine. The polysaccharide is kiwifruit polysaccharide A, kiwifruit polysaccharide B, kiwifruit polysaccharide C, kiwifruit polysaccharide D, and kif the same in tumor treatment and adjuvant used as vaccine. The polysaccharide is kiwifruit polysaccharide A, kiwifruit polysaccharide B, kiwifruit polysaccharide C, kiwifruit polysaccharide D, and kiwifruit total polysaccharide as a mixture containing the four kiwifruit polysaccharide, which are all extracted and separated from the Chinese medicinal herb of kiwifruit roots, and the polysaccharidewifruit total polysaccharide as a mixture containing the four kiwifruit polysaccharide, which are all extracted and separated from the Chinese medicinal herb of kiwifruit roots, and the polysaccharide has the remarkable antitumor and immunologic adjuvant function. The polysaccharides can obviously inhibit the growth of transplantation S180 caruncle and H22 liver cancer of a mouse, improve the breehas the remarkable antitumor and immunologic adjuvant function. The polysaccharides can obviously inhibit the growth of transplantation S180 caruncle and H22 liver cancer of a mouse, improve the breeder reaction of splenic cells of a tumor-bearing mice, the activity of NK cells and CTL, the ability of the splenic cells secreting IL-2 and IFN-Gamma, the level of tumor antigen specific antibodies Ider reaction of splenic cells of a tumor-bearing mice, the activity of NK cells and CTL, the ability of the splenic cells secreting IL-2 and IFN-Gamma, the level of tumor antigen specific antibodies IgG, IgG2a and IgG2b in blood serum of the tumor-bearing mouse, strengthen the humoral immunity and cell-mediated immunity response of an egg-albumin immunized mouse, induce the organism to produce Th1gG, IgG2a and IgG2b in blood serum of the tumor-bearing mouse, strengthen the humoral immunity and cell-mediated immunity response of an egg-albumin immunized mouse, induce the organism to produce Th1type and Th2 type immunity responses, and can be used as immunologic adjuvant of antineoplastic and tumor vaccine with immunity adjustment. type and Th2 type immunity responses, and can be used as immunologic adjuvant of antineoplastic and tumor vaccine with immunity adjustment.
Infants 6 weeks of age, part of the safety cohort, randomized to receive 3 doses of the iNTS-GMMA Dose B vaccine at Day 1, Day 57 (during the Priming phase) and at Day 232 (during the Booster phase). These infants also receive an EPI vaccination with Measles and Rubella Vaccine (MR-VAC) and Yellow Fever (YF) vaccine at 28 days after the third study intervention administration occurring at Day 232, at the local EPI vaccination centers, and not part of the current clinical trial.
Tudor Interacting Repair Regulator (TIRR) is an RNA-binding protein (RBP) that interacts directly with 53BP1, restricting its access to DNA double-strand breaks (DSBs) and its association with p53. We utilized iCLIP to identify RNAs that directly bind to TIRR within cells, identifying the long non-coding RNA NEAT1 as the primary RNA partner. The high affinity of TIRR for NEAT1 is due to prevalent G-rich motifs in the short isoform (NEAT1_1) region of NEAT1. This interaction destabilizes the TIRR/53BP1 complex, promoting 53BP1's function. NEAT1_1 is enriched during the G1 phase of the cell cycle, thereby ensuring that TIRR-dependent inhibition of 53BP1's function is cell cycle-dependent. TDP-43, an RBP that is implicated in neurodegenerative diseases, modulates the TIRR/53BP1 complex by promoting the production of the NEAT1 short isoform, NEAT1_1. Together, we infer that NEAT1_1, and factors regulating NEAT1_1, may impact 53BP1-dependent DNA repair processes, with implications for a spectrum of diseases.
This is an observational, non-interventional, multicenter study. The study will be performed within the Dutch GIST consortium (NKI-AvL, Erasmus MC, Radboud UMC, LUMC and UMCG). Patients diagnosed with GIST with a KIT exon 11 mutations that can be detected by our ddPCR assay are eligible. In this way we will study a homogenous patient population with GIST that (usually) responds very well to initial TKI treatment. Therefore, the KIT mutation status must be known. Patients can enter the study at any time point of their disease trajectory. Patients included in GALLOP-11 will have follow-up as described in the European Society of Medical Oncology and Dutch guidelines but with blood draws for ctDNA assessment at similar time points.

The primary objective is the negative predictive value (NPV) of the ddPCR assay result in relation to the results of the CT-scan and/or MRI scan (according to RECIST 1.1) at the same time point. Concordance of these results will be determined, from which the negative predictive value (NPV) of our ddPCR assay will be calculated. This is considered the most important value, as the most harmful scenario would be to miss progressive disease because not seen on ctDNA while it could have been seen on CT (and/or MRI). That would mean that ctDNA analysis is not reliable enough to replace CT-scan (and/or MRI) follow-up in the future.

To determine the negative predictive value, at least 250 patients need to have an evaluable follow-up strategy. To pursue a solid follow-up period within an achievable timeline, patients with at least four ctDNA measurements, accompanied by a CT-scan (and/or MRI scan), will be considered evaluable for the NPV analysis. Patients who have progression within four scans are always evaluable, since a positive outcome outweighs negative outcomes because it is known that ctDNA should have had measured change once it is seen on CT-scans (and/or MRI scans).
Transduction efficiencies of current viral vectors are inadequate to modify a sufficient number of tumor cells and achieve a relevant antitumor response. Replication of adenoviral vectors in tumor cells would amplify gene transduction. Adenoviral replication can be obtained in tumor cells by delivering genes essential for virus replication. Progeny virus are replication-defective, and the availability of replication-enabling genes limits the production of new cycles of replication. Cell viability determination showed that progeny virus specifically induced killing in GCV treated cells. A similar viral amplification effect was also shown in primary ovarian cancer cells derived from patients. Thus, this invention describes transcomplementation strategies to obtain replication of recombinant adenoviral vectors in ovarian tumor cells and in ovarian cancer primary cells.
PURPOSE: Frailty in older adult cancer survivors after cancer treatments is associated with various health outcomes. However, there is less agreement on how frailty affects symptoms and health-related quality of life (HRQOL). This systematic review and meta-analysis aimed to evaluate the current literature on frailty, symptoms, and HRQOL, as well as the associations of frailty with these factors in older adult cancer survivors with chemotherapy.
METHODS: A review was conducted on peer-reviewed publications from 2008 to 2023, using seven electronic databases. Meta-analyses were performed using random effects models to determine pooled effect estimates for frailty prevalence, symptom severity, and HRQOL scores.
RESULTS: A total of 26 studies involving older cancer survivors were included in the analysis. Most of these studies were conducted in Western countries and focused on White survivors, particularly those with breast cancer. The mean pooled prevalence of frailty was 43.5%. Among frail survivors, the most common symptoms reported after cancer treatments were pain (36.4%), neuropathy (34.1%), and fatigue (21.3%). Frailty was associated with higher pooled mean symptom severity (B = 1.23, p = 0.046) and lower functional HRQOL (B = - 0.31, p = 0.051, with marginal significance) after cancer treatments.
CONCLUSION: Frail older cancer survivors are at high risk of adverse symptoms and poor HRQOL after cancer treatment. Further research on screening for frailty is needed to prevent older adults from developing worse symptoms burden and maintain HRQOL. It is also essential to understand the mechanisms of the associations between frailty, symptoms and HRQOL in this population.
Detecting Alzheimer's disease (AD) accurately at an early stage is critical for planning and implementing disease-modifying treatments that can help prevent the progression to severe stages of the disease. In the existing literature, diagnostic test scores and clinical status have been provided for specific time points, and predicting the disease progression poses a significant challenge. However, few studies focus on longitudinal data to build deep-learning models for AD detection. These models are not stable to be relied upon in real medical settings due to a lack of adaptive training and testing. We aim to predict the individual's diagnostic status for the next six years in an adaptive manner where prediction performance improves with the number of patient visits. This study presents a Sequence-Length Adaptive Encoder-Decoder Long Short-Term Memory (SLA-ED LSTM) deep-learning model on longitudinal data obtained from the Alzheimer's Disease Neuroimaging Initiative archive. In the suggested approach, decoder LSTM dynamically adjusts to accommodate variations in training sequence length and inference length rather than being constrained to a fixed length. We evaluated the model performance for various sequence lengths and found that for inference length one, sequence length nine gives the highest average test accuracy and area under the receiver operating characteristic curves of 0.920 and 0.982, respectively. This insight suggests that data from nine visits effectively captures meaningful cognitive status changes and is adequate for accurate model training. We conducted a comparative analysis of the proposed model against state-of-the-art methods, revealing a significant improvement in disease progression prediction over the previous methods.
This study is a prospective, multicenter, single-arm phase II study. It is expected to include 20 patients with unresectable/metastatic pancreatic cancer who have relapsed after standard treatment, and they will be treated with a regimen of liposomal irinotecan combined with capecitabine. The main research unit is the Shenzhen Hospital of the Chinese Academy of Medical Sciences Cancer Hospital. The study includes a screening period (within 28 days), a treatment period (an estimated 6 cycles, until disease progression or intolerable toxicity occurs), and a follow-up period (12 months for safety follow-up and progression-free survival (PFS) follow-up). Participants sign an informed consent form and undergo baseline examinations during the screening period. Patients who meet the inclusion and exclusion criteria enter the treatment period, and all participants complete the relevant examinations stipulated by the protocol during the treatment process to observe safety, tolerability, and efficacy. The same participant will only receive one dosing plan during the study period. After the end of the treatment period, the follow-up period begins
BACKGROUND: Pre-diagnostic stages of psychotic illnesses, including 'clinical high risk' (CHR), are marked by sleep disturbances. These sleep disturbances appear to represent a key aspect in the etiology and maintenance of psychotic disorders. We aimed to examine the relationship between self-reported sleep dysfunction and attenuated psychotic symptoms (APS) on a day-to-day basis.
METHODS: Seventy-six CHR young people completed the Experience Sampling Methodology (ESM) component of the European Union Gene-Environment Interaction Study, collected through PsyMate® devices, prompting sleep and symptom questionnaires 10 times daily for 6 days. Bayesian multilevel mixed linear regression analyses were performed on time-variant ESM data using the brms package in R. We investigated the day-to-day associations between sleep and psychotic experiences bidirectionally on an item level. Sleep items included sleep onset latency, fragmentation, and quality. Psychosis items assessed a range of perceptual, cognitive, and bizarre thought content common in the CHR population.
RESULTS: Two of the seven psychosis variables were unidirectionally predicted by previous night's number of awakenings: every unit increase in number of nightly awakenings predicted a 0.27 and 0.28 unit increase in feeling unreal or paranoid the next day, respectively. No other sleep variables credibly predicted next-day psychotic symptoms or vice-versa.
CONCLUSION: In this study, the relationship between sleep disturbance and APS appears specific to the item in question. However, some APS, including perceptual disturbances, had low levels of endorsement amongst this sample. Nonetheless, these results provide evidence for a unidirectional relationship between sleep and some APS in this population.
PROBLEM TO BE SOLVED: To provide a method for supplying essential trace minerals by recovering trace element salts from sea water in the states of chemical species contained in the sea water and subsequently adding the recovered trace element salts to additives for staple foods or to common salt. SOLUTION: Sea water (bittern) left after the deposition and collection of salt from salt farm type salt water is frozen, and subsequently thermally concentrated to separate and collect magnesium sulfate (MgSO4 ), potassium chloride (KC1) and the potassium salt of bittern. The left water is further concentrated and dried to recover magnesium chloride (MgCl2 ) and trace element salts in sea water in a solid or flake state. The recovered product is frozen and subsequently ground. (1) The ground product is mixed with magnesium carbonate powder (CaCO3 ), and subsequently processed into a powdery, granular or plate- like additive for staple foods (rice, wheat flour). (2) The ground product is mixed with salt farm type salt to produce the trace mineral-mixed salt.
Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.